Navigation Links
Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
Date:10/23/2007

."

Of the 15 evaluable patients who achieved stable disease or PRs, eight remain on study and are continuing to receive additional cycles of treatment. Of note, four of the patients with measurable tumor shrinkage, including the two patients with PRs, previously failed prior platinum-containing regimens and treatment with doxorubicin HCl liposome injection (Doxil(R)). Of the 2 patients with PRs, one has received eight cycles of treatment and continues on study. The other patient progressed within 60 days of initial response.

Sunesis plans to enroll approximately 55 patients in this clinical trial. Thirty-one patients have been enrolled to date, and Sunesis expects to complete enrollment and present additional data in 2008.

"We are pleased to report SNS-595's early, yet positive, demonstration of clinical activity. We have met the pre-specified criterion to advance this compound to the second stage of our Phase 2 clinical trial, by showing sufficient evidence of anti-tumor activity," said Daniel C. Adelman, M.D., Senior Vice President, Development and Chief Medical Officer of Sunesis. "Additionally, the data suggests that SNS-595 may have potentially meaningful activity among platinum-resistant ovarian cancer patients who have also failed treatment with Doxil."

In parallel with the Phase 2 clinical trial, a non-clinical study was conducted to evaluate the activity of SNS-595 against 17 archived ovarian tumor biopsy specimens in the Extreme Drug Resistance (EDR(R)) cell proliferation assay. SNS-595 activity was compared to doxorubicin, etoposide and carboplatin -- agents used commonly in the treatment of ovarian cancer. Results from this study demonstrate that SNS-595 is a potent inhibitor of ovarian tumor cell growth, with activity comparing favorably to these agents. Further, none of the ovarian tumor samples showed any resistance to SNS-595.

These data were presented today during Poster Session A -- Clinical Trials at the AACR-NCI-EORT
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
2. Sunesis Pharmaceuticals Reports Positive Data From Studies of Two Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of the European Hematology Association
3. Sunesis Pharmaceuticals to Present Data at the 12th Congress of the European Hematology Association
4. Sunesis Presents Data Supporting SNS-032s Potential Anticancer Activity in Multiple Myeloma at the American Association for Cancer Research Meeting
5. Sunesis Pharmaceuticals to Present Data at the Annual Meeting of the American Association for Cancer Research
6. Sunesis Pharmaceuticals Presents SNS-314 Aurora Kinase Inhibitor Data Showing Broad Anti-Tumor Activity, Dosing Flexibility
7. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... , July 28, 2014  Air Products (NYSE: ... of medical oxygen is vital to any healthcare facility. ... that not only improve the efficiency of its oxygen ... will highlight these systems—including systems for emergency oxygen ... loss—from August 4-5 at the 51 st ...
(Date:7/28/2014)... July 28, 2014  Array BioPharma Inc. (Nasdaq: ... the fourth quarter and full year of ... to discuss those results on Tuesday, August ... and Michael Carruthers , Chief Financial ... August 12, 2014Time:9:00 a.m. Eastern TimeToll-Free:(800) 708-4540Toll:(847) ...
(Date:7/28/2014)...  Houston dentist , Dr. Behzad ... with Invisalign. With access to this increasingly popular ... straightened without feeling self-conscious in the process. Invisalign ... types of braces, but patients who choose Invisalign ... better support for their oral health and comfort ...
Breaking Medicine Technology:Air Products Highlights Its Medical Oxygen Supply Systems for Emergency Oxygen Supply and Reduced Oxygen Loss at ASHE 2Air Products Highlights Its Medical Oxygen Supply Systems for Emergency Oxygen Supply and Reduced Oxygen Loss at ASHE 3Houston Cosmetic Dentist, Dr. Behzad Nazari, Now Offers Orthodontic Treatment with Invisalign 2
... the Academy of Managed Care Pharmacy (AMCP) 2010 ... week, Express Scripts (Nasdaq: ESRX ) ... for driving down healthcare costs and providing increased ... (Logo:   http://photos.prnewswire.com/prnh/20080827/EXPRESSSCRIPTSLOGO ) (Logo: ...
... DIEGO, Oct. 13 RESMED INC. (NYSE: RMD ... will release its results for the first quarter of fiscal ... ResMed,s results will be issued after 1:00 p.m. Pacific Time ... to review its results, market trends, and future outlook. ...
Cached Medicine Technology:Express Scripts Unveils New Opportunities to Drive Down Healthcare Costs; Presents Five Studies at Academy of Managed Care Pharmacy Conference 2Express Scripts Unveils New Opportunities to Drive Down Healthcare Costs; Presents Five Studies at Academy of Managed Care Pharmacy Conference 3ResMed Announces Conference Call and Webcast to Discuss First Quarter 2011 Results 2
(Date:7/28/2014)... 2014 The North America Carotenoids & Antioxidants ... in North America with analysis and forecast of revenue. This ... 2012 to $812.7 million by 2018, at a CAGR of ... of the North America Carotenoids & Antioxidants Market report to ... provides a glimpse of the segmentation in the market, and ...
(Date:7/28/2014)... (HealthDay News) -- A common inflammatory muscle disorder ... may increase the risk for heart attack and ... study found that patients with polymyalgia rheumatica are ... that affect the blood vessels. Doctors should carefully ... polymyalgia rheumatica to reduce their risk for complications, ...
(Date:7/28/2014)... 2014 The Oneida Indian Nation today ... field of accompanying PGA TOUR players will be teeing ... Notah Begay III for the seventh annual Notah Begay ... Resort Casino ’s Atunyote® Golf Club on Wednesday, August ... Jason Dufner, Jimmy Walker, Jonas Blixt, Angel Cabrera and ...
(Date:7/28/2014)... 2014A two-step decision tree analysis, incorporating Donabedian,s model, ... the many available quality standards, guidelines, recommendations and ... international quality standards for radiation therapy, according to ... of Practical Radiation Oncology (PRO), the ... for Radiation Oncology (ASTRO). , Guidelines, recommendations and ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 In response ... Americans face today, BlogHer, The Center for American Progress ... “Make Life Work,” a campaign to raise awareness and ... across the U.S. The joint initiative was announced on ... Editor-in-Chief, BlogHer; Judith Warner, Senior Fellow, The Center for ...
Breaking Medicine News(10 mins):Health News:North America Carotenoids & Antioxidants (Nutraceuticals) Market is Expected to Reach $812.7 Million in 2018 - New Report by MicroMarket Monitor 2Health News:North America Carotenoids & Antioxidants (Nutraceuticals) Market is Expected to Reach $812.7 Million in 2018 - New Report by MicroMarket Monitor 3Health News:North America Carotenoids & Antioxidants (Nutraceuticals) Market is Expected to Reach $812.7 Million in 2018 - New Report by MicroMarket Monitor 4Health News:Inflammatory Muscle Disorder May Raise Risk for Heart Attack, Stroke 2Health News:Turning Stone Announces that Tiger Woods and Fellow Golfing Elites Will Play at the Seventh Annual Notah Begay III Foundation Challenge 2Health News:Turning Stone Announces that Tiger Woods and Fellow Golfing Elites Will Play at the Seventh Annual Notah Begay III Foundation Challenge 3Health News:Turning Stone Announces that Tiger Woods and Fellow Golfing Elites Will Play at the Seventh Annual Notah Begay III Foundation Challenge 4Health News:Turning Stone Announces that Tiger Woods and Fellow Golfing Elites Will Play at the Seventh Annual Notah Begay III Foundation Challenge 5Health News:Two-step decision tree analysis helps inform updates of RT best practices, quality standards 2Health News:Two-step decision tree analysis helps inform updates of RT best practices, quality standards 3Health News:“Make Life Work” Campaign Launches to Address the Needs of Today's Working Families & Promote Realistic Solution 2Health News:“Make Life Work” Campaign Launches to Address the Needs of Today's Working Families & Promote Realistic Solution 3Health News:“Make Life Work” Campaign Launches to Address the Needs of Today's Working Families & Promote Realistic Solution 4Health News:“Make Life Work” Campaign Launches to Address the Needs of Today's Working Families & Promote Realistic Solution 5
... new government report shows, , WEDNESDAY, Aug. 19 (HealthDay News) ... 78 years, a record high, federal health officials said Wednesday. ... rate has dropped to an all-time low of 760.3 deaths ... U.S. Centers for Disease Control and Prevention. , "It is ...
... , , MINNETONKA, Minn., ... technology solutions company specializing in clinical study management systems, today ... named to the Inc. 5000, Inc . magazine,s annual ... rapid, yet controlled revenue growth over the last four years ...
... LEXINGTON, Ky., Aug. 19 VirtualHealth Technologies, Inc. (OTC Bulletin ... relation to the announcement made earlier this week on August 17th ... and restructuring fees as well as VHGI,s agreement to revise the ... of the August 17th release please go to http://www.virtu ...
... University have found exposure to the hormone progesterone activates ... This progesterone-induced inflammation may be a key factor ... is a naturally occurring steroid hormone and promotes development ... identified as a risk factor for breast cancer, and ...
... the University of Pittsburgh School of Medicine have shown that ... is required for their biological activity. This shape-changing also allows ... to select the structure that permits the best binding. That ... that will have the most impact on protein function to ...
... , ORLANDO, Fla., Aug. ... developed technology that has dramatically increased the stability and ... has just completed a 7-year shelf-life study of its ... supercritical CO2 extract of Haematococcus pluvialis, bolstered by Valensa,s ...
Cached Medicine News:Health News:Life Expectancy in U.S. Hits a New High 2Health News:Life Expectancy in U.S. Hits a New High 3Health News:MedNet Solutions Named to the Inc. 5000 List Three Years in a Row 2Health News:VirtualHealth Technologies Files 8k Related to the August 17th Announcement of Private Access Payment and Document Modification 2Health News:VirtualHealth Technologies Files 8k Related to the August 17th Announcement of Private Access Payment and Document Modification 3Health News:MSU scientists: Progesterone leads to inflammation 2Health News:Pitt scientists find intrinsic changes in protein shape influence drug binding 2Health News:Astaxanthin Stability Breakthrough Achieved by Valensa 2Health News:Astaxanthin Stability Breakthrough Achieved by Valensa 3